Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer

被引:30
|
作者
Yang, Zhengyang
Wu, Guocong
Zhang, Xiao
Gao, Jiale
Meng, Cong
Liu, Yishan
Wei, Qi
Sun, Liting
Wei, Pengyu
Bai, Zhigang [1 ]
Yao, Hongwei [1 ]
Zhang, Zhongtao [1 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
colorectal cancer; PD-1; PD-L1; inhibitors; neoadjuvant; microsatellite instability; mismatch repair; IMMUNE CHECKPOINT INHIBITORS; MISMATCH REPAIR-DEFICIENT; ADVANCED RECTAL-CANCER; REGULATORY T-CELLS; MICROSATELLITE INSTABILITY; PD-1; BLOCKADE; PD-1/PD-L1; POOLED ANALYSIS; OPEN-LABEL; IMMUNOTHERAPY;
D O I
10.3389/fimmu.2022.1001444
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1/PD-L1 inhibitors are mainly used according to the mutation pattern, which is categorized into deficient mismatch repair (dMMR)/high levels of microsatellite instability (MSI-H) and proficient mismatch repair (pMMR), or non-high levels of microsatellite instability (non-MSI-H). PD-1/PD-L1 inhibitors have been proven to have favorable outcomes against dMMR/MSI-H CRC because of more T-cell infiltration into tumor tissues. Nevertheless, the effectiveness of PD-1/PD-L1 inhibitors in pMMR/non-MSI-H CRC is still uncertain. Because of the quite-lower proportion of dMMR/MSI-H in CRC, PD-1/PD-L1 inhibitors have been reported to combine with other antitumor treatments including chemotherapy, radiotherapy, and targeted therapy for better therapeutic effect in recent clinical trials. Neoadjuvant therapy, mainly including chemotherapy and radiotherapy, not only can reduce clinical stage but also benefit from local control, which can improve clinical symptoms and the quality of life. Adding immunotherapy into neoadjuvant therapy may change the treatment strategy of primary resectable or some metastatic CRC. In this review, we focus on the development of neoadjuvant anti-PD-1/PD-L1 therapy and discuss the future perspectives in CRC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
    Chen, Xiang
    Chen, Ling-Juan
    Peng, Xiao-Fei
    Deng, Ling
    Wang, Yan
    Li, Jiu-Jiang
    Guo, Dong-Li
    Niu, Xiao-Hua
    [J]. TRANSLATIONAL ONCOLOGY, 2024, 40
  • [2] Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
    Chen, Lieping
    Han, Xue
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09): : 3384 - 3391
  • [3] Pneumonitis with anti-PD-1/PD-L1 therapy
    Naidoo, J.
    Cunningham, J.
    Woo, K. M.
    Hellmann, M. D.
    Postow, M. A.
    Drilon, A. E.
    Chaft, J. E.
    Lesokhin, A. M.
    Segal, N. H.
    Callahan, M. K.
    Rudin, C. M.
    Iyriboz, T.
    Wolchok, J. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
  • [4] Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
    de Jong, Florus C.
    Rutten, Vera C.
    Zuiverloon, Tahlita C. M.
    Theodorescu, Dan
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 15
  • [5] Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
    Sundararajan, Srinath
    Vogelzang, Nicholas J.
    [J]. FUTURE ONCOLOGY, 2015, 11 (16) : 2299 - 2306
  • [6] Pneumonitis From Anti-PD-1/PD-L1 Therapy
    Balaji, Aanika
    Verde, Franco
    Suresh, Karthik
    Naidoo, Jarushka
    [J]. ONCOLOGY-NEW YORK, 2017, 31 (10): : 739 - +
  • [7] Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
    Wang, Luyao
    Ma, Qingxia
    Yao, Ruixue
    Liu, Jia
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 79
  • [8] IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study
    Yuan, Wenli
    Deng, Deyao
    Li, Hanyu
    Hu, Xinghui
    Shang, Xueqin
    Hou, Xia
    Jiang, Hongchao
    He, Hongchun
    [J]. ONCOTARGETS AND THERAPY, 2021, 14 : 3051 - 3062
  • [9] Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
    Yang, Bo
    Liu, Tingjun
    Qu, Yang
    Liu, Hangbo
    Zheng, Song Guo
    Cheng, Bin
    Sun, Jianbo
    [J]. FRONTIERS IN ONCOLOGY, 2018, 8
  • [10] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
    Sui, Xinbing
    Ma, Junhong
    Han, Weidong
    Wang, Xian
    Fang, Yong
    Li, Da
    Pan, Hongming
    Zhang, Li
    [J]. ONCOTARGET, 2015, 6 (23) : 19393 - 19404